Lepodisiran

1. Lepodisiran decreases OxPL-apoB in humans (-88.5% (95% CI: -90.4% to -86.3%)).

   Human trialplacebo-adjusted geometric mean in 400-mg dose group at day 240400 mgday 240n = 213

   Effect on Lipoprotein(a) Oxidized Phospholipids of Lepodisiran, an Extended-Duration siRNA Targeting Lipoprotein(a) · Journal of the American College of Cardiology · 31 Aug 2026

OxPL-apoB →

1. Lepodisiran decreases OxPL-apo in humans (-94.2% (95% CI: -95.7% to -92.2%)).

   Human trialplacebo-adjusted geometric mean in 400-mg dose group at day 240400 mgday 240n = 213

   Effect on Lipoprotein(a) Oxidized Phospholipids of Lepodisiran, an Extended-Duration siRNA Targeting Lipoprotein(a) · Journal of the American College of Cardiology · 31 Aug 2026

OxPL-apo →